Imlifidase denied for failing step therapy by Aetna?
Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna's specific coverage criteria for imlifidase are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Aetna angle on Imlifidase
## Why Aetna Applied Step Therapy to Imlifidase — and How to Appeal
Step therapy (also called "fail first") requires that a patient try and fail one or more less expensive or more established treatments before the insurer will authorize a requested drug. For imlifidase — a specialized desensitization agent used in kidney transplantation — a step-therapy denial may reflect Aetna's policy that certain prior treatment pathways or desensitization approaches must be documented as tried or considered before imlifidase is approved. This can seem clinically inappropriate given the highly specific and narrow indication for this agent.
## Why This Denial Is Appealable
Step-therapy requirements are subject to override (sometimes called a "step-therapy exception") when the required prior therapy is: (a) contraindicated or likely to cause adverse effects in the specific patient, (b) clinically inferior for the patient's particular condition, (c) already tried and failed, or (d) simply inapplicable given the clinical scenario. Many states have enacted step-therapy exception laws that mandate a decision timeline and substantive review standards — check your state's insurance laws. For ERISA-governed employer plans, ERISA §503 full-and-fair review applies. For ACA-compliant insured plans, ACA §2719 external review is available after internal exhaustion.
## Federal Appeal Framework
- Step-therapy exception request (internal): This is typically filed as a prior-authorization appeal or exception request. Aetna must decide within 30 days for standard pre-service reviews.
- Expedited review: If the clinical situation is urgent (e.g., transplant is scheduled), request expedited review — Aetna must respond within 72 hours.
- External review: If the internal appeal or exception request is denied, escalate to independent external review under ACA §2719. External reviewers frequently overturn step-therapy denials where the required prior therapy is clinically inapplicable.
- State step-therapy exception law: Many states have passed specific step-therapy exception statutes. Your state insurance department can confirm whether these apply to your plan.
## Documentation to Gather
- Clinical rationale for exception: The transplant physician must explain in writing why the step-therapy requirement does not apply — for example, why prior required therapies were tried and failed, contraindicated per the physician's clinical judgment, or simply not applicable to transplant desensitization.
- Diagnosis and sensitization records: Documentation establishing the transplant indication and sensitization profile.
- Prior treatment history with dates and outcomes: A chronological list of all prior relevant treatments, including outcomes, to demonstrate what has been tried.
- Prescriber letter of medical necessity: Explicitly addressing each step-therapy requirement in Aetna's CPB and explaining why imlifidase is the appropriate next step.
- Society guidelines: Your physician should reference applicable transplant medicine society recommendations (without quoting specific statistics) to show that imlifidase is consistent with accepted medical practice for this indication.
## Criteria-Mapping Structure
Obtain Aetna's clinical policy bulletin (CPB) and its step-therapy requirements. Then map each step to your evidence:
| Step-Therapy Requirement | Documentation Provided | |---|---| | Prior therapy 1 tried/failed | Chart note + date + outcome | | Prior therapy 2 tried/failed or not applicable | Prescriber explanation | | Exception ground (contraindication / clinical inapplicability) | Physician letter + chart support | | Imlifidase consistent with guidelines | Society guideline citation |
A strong step-therapy appeal combines a prescriber letter that speaks directly to each required step with a factual demonstration — not just assertion — that those steps were completed, inapplicable, or harmful.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →